Evidence for efficacy of new hsp90 inhibitors revealed by ex vivo culture of human prostate tumors

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3562-3570

  Centenera, Margaret M ^a   Gillis, Joanna L ^a   Hanson, Adrienne R ^a   Jindal, Shalini ^a   Taylor, Renea A ^c   Risbridger, Gail P ^c   Sutherland, Peter D ^b   Scher, Howard I ^d   Raj, Ganesh V ^e   Knudsen, Karen E ^f   Yeadon, Trina ^a   Tilley, Wayne D ^a   Butler, Lisa M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; NVP HSP 990; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN; CELL STRAIN LNCAP; CELL STRAIN PC 3; CELL STRAIN VCAP; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN SYNTHESIS INHIBITION; TUMOR CELL CULTURE;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CELL PROLIFERATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PYRIDONES; PYRIMIDINES; RESORCINOLS; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED;

EID: 84863335299     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0782     Document Type: Article

References (29)

1. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
2. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26:3409-16. (Pubitemid 44701516)
3. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
4. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93. (Pubitemid 34517631)
5. Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002;7:55-64. (Pubitemid 36138904)
6. Williams CR, Tabios R, Linehan WM, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 2007;178: 1528-32. (Pubitemid 47376711)
7. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61. (Pubitemid 46211321)
8. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 2005;4:138-41. (Pubitemid 41474610)
9. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010;28:1520-6.
10. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
11. Pacey S, Wilson RH, Walton MI, Eatock M, Hardcastle A, Zetterlund A, et al.Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors. Clin Cancer Res 2011;17:1561-70.
12. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823:742-55.
13. Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000;19: 4383-92. (Pubitemid 30623749)
14. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
15. Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther 2012;11:730-9.
16. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9: 1219-33.
17. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
18. Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, et al. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nucl Med Biol 2009;36:335-42.
19. Samuel TA, Sessa C, Britten C, Milligan KS, Mita MM, Banerji U, et al. AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. ASCO Meeting Abstracts 2010;28:2528.
20. Khong T, Spencer A. Targeting heat shock protein 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
21. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, et al. Suberoylanilide hydoxamic acid (SAHA; vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007;6:51-60. (Pubitemid 46209918)
22. Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010;15: 31-8.
23. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, et al.A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011;17:2301-13.
24. Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010;16:4779-88.
25. Kang BH, Tavecchio M, Goel HL, Hsieh CC, Garlick DS, Raskett CM, et al. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer 2011;104:629-34.
26. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14:7940-6.
27. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010;46:340-7.
28. Arya R, Mallik M, Lakhotia SC. Heat shock genes - integrating cell survival and death. J Biosci 2007;32:595-610. (Pubitemid 46708710)
29. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64. (Pubitemid 43881318)